ipilimumab Cancer Research Results

lpi, ipilimumab: Click to Expand ⟱
Features: Immunomodulatory antibodies
Two different inhibitory pathways that block antitumor T cell responses.

Ipilimumab — a fully human recombinant IgG1κ monoclonal antibody and immune-checkpoint inhibitor that binds cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). It is formally classified as an antineoplastic immunotherapy / CTLA-4-blocking monoclonal antibody. Standard abbreviations include IPI and ipi; the marketed formulation is Yervoy. Ipilimumab is produced in Chinese hamster ovary cells and is administered intravenously. Unlike a directly cytotoxic drug, its principal antitumor action is mediated by releasing inhibitory constraints on T-cell immunity. It was the first CTLA-4 inhibitor approved for cancer therapy and remains clinically important primarily as monotherapy in selected melanoma settings and, more commonly, as part of combination immunotherapy such as nivolumab plus ipilimumab.

Primary mechanisms (ranked):

  1. CTLA-4 blockade: binds CTLA-4 on activated T cells and regulatory T cells, inhibiting CTLA-4 interaction with the B7 ligands CD80/CD86 and thereby reducing a major inhibitory checkpoint on T-cell activation.
  2. Enhanced CD28-dependent T-cell costimulation and priming: preservation of CD80/CD86 availability for CD28 increases activation, proliferation, cytokine production, and expansion of tumor-reactive effector T cells.
  3. Increased intratumoral effector T-cell activity and effector-to-regulatory T-cell balance, promoting immune-mediated tumor-cell killing.
  4. Modulation of regulatory T-cell function: CTLA-4 blockade can diminish Treg-mediated immune suppression; Fcγ-receptor-dependent depletion of intratumoral Tregs has strong preclinical support but appears variable and incomplete in human tumors.
  5. Immune diversification and expansion of antitumor T-cell clones, potentially broadening recognition of tumor-associated antigens and contributing to durable immune memory.
  6. Complementarity with PD-1 blockade: CTLA-4 inhibition acts predominantly during T-cell priming and early activation, whereas PD-1 inhibition acts strongly within peripheral tissues and the tumor microenvironment; combined inhibition can produce greater antitumor activity than either pathway alone in several cancers.

Bioavailability / PK relevance: Intravenous administration provides complete systemic availability. Ipilimumab is a large approximately 148-kDa monoclonal antibody with linear pharmacokinetics over approximately 0.3–10 mg/kg. The mean terminal half-life is approximately 15.4 days and mean systemic clearance approximately 16.8 mL/hour. With every-3-week dosing, systemic accumulation is generally 1.5-fold or less and steady-state concentrations are reached by approximately the third dose. Distribution into solid tumors is governed by antibody extravasation, tumor vascularity, stromal accessibility, CTLA-4-expressing immune-cell abundance, and Fc-receptor biology rather than passive small-molecule diffusion.

In-vitro vs systemic exposure relevance: Conventional small-molecule concentration comparisons are not directly applicable. Ipilimumab acts through high-affinity receptor occupancy and immune-network modulation rather than nonspecific exposure-driven tumor cytotoxicity. Clinically relevant activity depends substantially on CTLA-4 expression, immune-cell composition, T-cell priming, intratumoral inflammation, Fcγ-receptor context, and combination therapy. Direct tumor-cell effects observed in isolated culture systems should therefore not be interpreted as the primary clinical mechanism unless the model contains the appropriate immune components.

Clinical evidence status: Established clinical therapy with extensive randomized-trial evidence and regulatory approval. Ipilimumab has demonstrated durable survival benefit in melanoma and is FDA-authorized either alone or, depending on cancer type, with nivolumab for melanoma, advanced renal-cell carcinoma, MSI-H/dMMR colorectal cancer, hepatocellular carcinoma, non-small-cell lung cancer, malignant pleural mesothelioma, and esophageal squamous-cell carcinoma. Long-term randomized data support particularly durable responses with nivolumab plus ipilimumab. Major clinical limitations are immune-mediated toxicities including colitis, hepatitis, dermatitis, endocrinopathies, pneumonitis, nephritis, and rarer severe or fatal inflammatory syndromes; these adverse effects reflect the same systemic immune disinhibition responsible for therapeutic activity.

Ipilimumab Cancer-Relevant Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 CTLA-4 checkpoint signaling Indirect ↓ immune escape ↓ CTLA-4-mediated inhibitory signaling in activated T cells and Tregs R/G Removes inhibitory control of antitumor T-cell responses Core mechanism. Ipilimumab binds CTLA-4 and inhibits its interaction with CD80/CD86. The principal target is the immune system rather than the malignant cell itself.
2 CD28 and CD80/CD86 costimulation Indirect ↑ immune recognition and killing ↑ CD28-mediated T-cell costimulation R/G ↑ T-cell activation, proliferation, and effector differentiation CTLA-4 normally competes strongly with CD28 for CD80/CD86. Blocking CTLA-4 shifts signaling toward productive costimulation.
3 CD8-positive effector T-cell response ↑ immune-mediated apoptosis and elimination ↑ activation and expansion of tumor-reactive CD8-positive T cells G Enhances cytotoxic antitumor immunity Clinically important downstream consequence rather than direct cytotoxicity by ipilimumab.
4 Regulatory T-cell suppression Indirect ↓ immune escape ↓ suppressive Treg function G Raises the effector-to-regulatory T-cell ratio CTLA-4 is constitutively high on Tregs. Functional suppression is better established than uniform physical depletion in patients.
5 Fcγ receptor dependent intratumoral Treg depletion Indirect ↓ immune suppression ↓ CTLA-4-high intratumoral Tregs (context-dependent) G Potential ADCC or phagocytic removal of suppressive Tregs Mechanistically important in preclinical models. Human data are mixed; conventional ipilimumab appears to produce less consistent Treg depletion than optimized Fc-engineered anti-CTLA-4 antibodies.
6 Effector T-cell to Treg ratio Indirect ↓ immune tolerance ↑ CD8-positive or effector T-cell to Treg ratio G Shifts the tumor microenvironment toward immune activation Can arise from effector expansion, reduced Treg function, and in some settings Fc-dependent Treg depletion.
7 T-cell clonal expansion and repertoire diversification Indirect ↑ antigen-directed killing ↑ expansion and diversification of activated T-cell clones G Broadens antitumor immune recognition May help explain delayed responses, long-lived immune memory, and durable tumor control after limited dosing.
8 Pro-inflammatory cytokine signaling Indirect ↑ immune pressure ↑ activated T-cell cytokine production (context-dependent) R/G Strengthens cell-mediated antitumor responses Not a single defined cytokine pathway; enhanced IFN-γ and related effector programs commonly accompany checkpoint release.
9 PD-1 combination sensitization ↑ susceptibility to immune clearance ↑ complementary T-cell priming and peripheral effector activity G Synergistic dual-checkpoint inhibition Clinically central. CTLA-4 and PD-1 are distinct checkpoints; ipilimumab itself does not inhibit PD-1. Combination with nivolumab improves efficacy in several cancers but also increases immune-related toxicity.
10 Immune memory and durable surveillance ↓ recurrent immune escape in responding tumors ↑ persistent tumor-reactive memory T-cell populations G Supports long-duration responses after finite treatment Durable survival plateaus in long-term melanoma studies are characteristic of effective checkpoint immunotherapy.
11 Immune-mediated normal tissue inflammation ↔ ↑ autoreactive and inflammatory immune activity G Causes immune-related adverse events Clinically important on-target liability. Colitis, hepatitis, dermatitis, endocrinopathies, pneumonitis, nephritis, myocarditis, and neurologic toxicities may occur, including after therapy has stopped.
12 Clinical Translation Constraint Response depends on tumor immunogenicity and immune infiltration Systemic checkpoint inhibition limits therapeutic window G Variable response with potentially severe immune toxicity Major constraints include nonresponse in immunologically cold tumors, lack of a universally reliable predictive biomarker, heterogeneous Fcγ-receptor biology, delayed immune toxicity, and increased adverse-event burden with combination checkpoint blockade.

P: 0–30 min     R: 30 min–3 hr     G: >3 hr
Scientific Papers found: Click to Expand⟱
7708- ,  lpi,    Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
- Trial, CRC, NA
PFS↑,
7706- lpi,  NIV,    Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
- Trial, Melanoma, NA
OS↑,
7707- NIV,  lpi,    Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
- Trial, RCC, NA
OS↑, Dose↝,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

PFS↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 2,  
Total Targets: 3

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:21  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page